Email Print PDF Bookmark | | More

BioInvent International AB

Biotech Company / Biological Products

Pipeline

Staff

Contact

Member of Medicon Valley Alliance

Description

BioInvent International AB focuses on developing antibody drugs. The proprietary fully human Ab library n-CoDeR and in-house cGMP manufacturing form a powerful platform for Ab drug development. Together with partners such as Roche, Genentech, Bayer HealthCare, ThromboGenics and UCB, BioInvent runs projects within the areas of thrombosis, cancer and atherosclerosis.

Drug Pipeline

BI-204 [Internal project]

BI-204 is a human antibody which targets the oxidised form of a low-density lipoprotein (LDL), called apoB100. BI-204 is being developed as a treatment for atherosclerosis, aimed at reducing the occurrence of heart attacks in high-risk patients. These are primarily patients with acute coronary artery disease, particularly those who have already suffered a heart attack. GLACIER was a randomized, placebo-controlled, double-blind,multicentre phase II study, where BI-204 was delivered intravenously to patients with stable coronary artery disease on top of standard-of-care. In July 2012 BioInvent annonced that the study did not meet the primary endpoint.

Drug development

Therapeutical Area / Indication		Pre- clinical	Phase I	Phase II	Phase III	Phase IV
Heart and Blood Diseases
	Atherosclerosis

TB-403 [Co-developed with Roche]

TB-403 is a humanised monoclonal antibody that blocks the activity of Placenta Growth Factor (PlGF), a protein involved in the development of new blood vessels (angiogenesis). TB-403's ability to block the growth of new blood vessels and modulate inflammation means it could potentially be used in a broad range of cancer and non-cancer indications.

Drug development

Therapeutical Area / Indication		Pre- clinical	Phase I	Phase II	Phase III	Phase IV
Cancers and Other Neoplasms
	Glioblastoma

BI-505 [Internal project]

BI-505 is a fully human antibody derived from BioInvent's proprietary n-CoDeR® library. The antibody binds to the adhesion protein ICAM-1 (CD54), which is over expressed in several tumours but is not widely expressed in normal tissue. BI-505 is being developed to treat multiple myelomas that express ICAM-1. BI-505 has been granted orphan drug designation for the treatment of multiple myeloma by both the FDA and the European Agency for the Evaluation of Medicines (EMEA).